Not yet recruiting NCT07642648
A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Novel Herbal Cold & Flu Blend, Placebo.
- Who it may be relevant to
- Registry conditions: URTI, Common Cold. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized Blinded Controlled Trial Evaluating the Efficacy of a Novel Herbal Cold and Flu Blend in Reducing the Duration and Severity of Symptoms of the Common Cold
Overview
The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \& Flu Blend in reducing the duration of symptoms of the common cold. The secondary objective is to assess whether the investigational product reduces the severity of symptoms. Participants will be enrolled for 16 weeks, during this period they will take the assigned study product when they experience URTI symptoms.
Interventions
- Dietary supplement Novel Herbal Cold & Flu Blend
Each 485mg capsule contains the Novel Herbal Cold \& Flu Blend. Participants will start taking the study product if they experience 2 or more URTI symptoms (as per the WURSS-24) or a fever above 38.0°C. Participants are to consume 2 capsules three times each day until symptoms resolve. - Other Placebo
Each placebo capsule contains Microcrystalline cellulose, Colloidal Silicon dioxide, Magnesium Stearate and Sodium Metabisulfite. Participants will start taking the study product if they experience 2 or more URTI symptoms (as per the WURSS-24) or a fever above 38.0°C. Participants are to consume 2 capsules three times each day until symptoms resolve.
Primary outcome measures
- Cumulative number of days that participant recorded symptom positive on the WURSS-24 scoring system [Time frame: Baseline to week 16]
Secondary outcome measures (6)
- Symptom severity based on the total sum of all parameters in the WURSS-24 scoring system. [Time frame: Baseline to week 16]
- Cumulative scores of each individual parameter in the Wisconsin Upper Respiratory Symptom Survey (WURSS-24) scoring system.. [Time frame: Baseline to week 16]
- Number of days of absence from work / school. [Time frame: Baseline to week 16]
- Perception of efficacy rated on the Treatment Satisfaction VAS. [Time frame: Baseline to week 16]
- Safety via Adverse Event reporting and incident rate ratio between active and placebo groups [Time frame: Baseline to week 16]
- Use of rescue medication for an URTI [Time frame: Baseline to week 16]
Eligibility criteria
Inclusion criteria
- Adults aged 18-65 years living in Australia
- Individuals with a history of recurrent Upper Respiratory Tract infections (URTI) (at least one episode per year)
- Able to provide informed consent
- Generally healthy
- Agree to not participate in another clinical trial while enrolled in this trial
- Agree to maintain their usual daily activities without significant changes. This includes not changing their current diet or stopping/starting a new exercise regimen during entire study period
- Females of childbearing potential must use a prescribed form of birth control (e.g. oral contraceptive)
Exclusion criteria
- Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, autoimmune conditions, neurological disorders such as multiple sclerosis.
- Unstable illness e.g., changing medication/treatment.
- BMI <18.5, >30
- Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.
- Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease).
- Active smokers, nicotine use (including vaping/e-cigarettes) or drug (prescription or illegal substances) abuse
- Current alcohol use (>21 alcoholic drinks week)
- Allergic to any of the ingredients in the active or placebo formula
- Allergic to plants in the Asteraceae family
- Pregnant or lactating woman
- Regular use of medications that would affect the immune and/or the inflammatory response e.g. antihistamines, anti-inflammatories, immunosuppressants, steroids excluding topical steroid use.
- Use of anticoagulant medications such as warfarin.
- Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month
- Participants with allergic rhinitis
- Regular use of antihistamines
- Individuals deemed unsuitable for participation by the Principal Investigator (PI) of this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07642648 · NOURTI